Actuate Therapeutics (ACTU) Earnings Analysis

Actuate Therapeutics (ACTU) next reports earnings on 2026-08-13, consensus EPS -0.21 USD. Last quarter (2026-05-14) it missed with EPS -0.24 USD vs -0.23 USD est (-4.3%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E -1.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ACTU next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.21 USD
Revenue estimaten/a

ACTU earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.24 USD-0.23 USD-4.3%Miss
2026-03-26-0.18 USD-0.24 USD+25%Beat
2025-11-13-0.25 USD-0.27 USD+7.4%Beat
2025-08-14-0.3 USD-0.19 USD-57.9%Miss
2025-05-15-0.32 USD-0.3 USD-6.7%Miss
2025-03-13-0.33 USD-0.29 USD-13.8%Miss
2024-11-13-0.55 USD-0.55 USD0%Beat

Beat rate: 3/7 (43%) over reported quarters with consensus data.

ACTU valuation and analyst view

Trailing P/E-1.28
Trailing EPS-0.915 USD
Price / book7.87
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (1 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Actuate Therapeutics (ACTU)'s next earnings date?

Actuate Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.21 USD.

Did ACTU beat earnings last quarter?

In its 2026-05-14 report, ACTU posted EPS of -0.24 USD versus a -0.23 USD estimate — a miss of 4.3%.

What is ACTU's earnings track record?

Over the last 7 reported quarters with consensus data, ACTU beat estimates 3 times (43%).

What is ACTU's current P/E ratio and EPS?

ACTU trades at a trailing P/E of -1.28 on trailing EPS of -0.9150042226891345 USD.

What do analysts rate ACTU?

Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell).